Crescent Biopharma Grants 24,600 Options at $9.33 Exercise Price
Crescent Biopharma’s Compensation Committee approved 24,600 stock options to two non-executive employees under its 2025 Inducement Plan, with a 10-year term and $9.33 exercise price set on February 17, 2026. Options vest 25% after one year and monthly thereafter over three additional years.
1. Awards Approved by Compensation Committee
On February 17, 2026, the Compensation Committee approved inducement awards of 24,600 options to two non-executive employees under the 2025 Employment Inducement Incentive Award Plan, marking a material condition for their acceptance of employment with the company.
2. Option Terms and Exercise Price
Each option carries a 10-year term with an exercise price of $9.33 per share, matching the closing price reported on the grant date, and is governed by the terms of the Inducement Plan and individual option agreements.
3. Vesting Schedule
The options vest 25% after the first anniversary of each employee’s start date and vest in equal monthly installments (1/48th per month) thereafter, contingent on continuous service through each vesting date.
4. Potential Impact on Equity
The grant represents additional potential dilution as employees exercise options over the next decade, though full realization depends on future share price performance and continued service.